跳至主要内容
临床试验/NCT07223606
NCT07223606No Longer Available不适用

Fecal Microbiota Transplant for Neuroblastoma in a Single Patient

ProgenaBiome1 个研究点 分布在 1 个国家开始时间: 2025年11月3日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
No Longer Available
发起方
试验地点
1

研究概览

简要总结

This study uses fecal microbiota transplant (FMT) to correct gut microbiome dysbiosis prior to and during standard-of-care neuroblastoma treatment

详细描述

Patients with neurobastoma and concurrent dysbiosis showing a bifidobacteria-bacteroides gap will undergo fecal microbiota transplant as an adjunctive to standard-of-care oncology treatment.

研究设计

研究类型
Expanded Access

入排标准

年龄范围
5 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •willingness of parent/guardian to sign ICF
  • •diagnosis of neuroblastoma
  • •dysbiosis of the gut microbiome

排除标准

  • •parent/guardian unwilling to sign ICF
  • •dysbiosis does not show a bifidobaceteria-bacteroides gap
  • •severely abnormal screening lab values

研究者

发起方
ProgenaBiome
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验